On the 12th of September, Hyderabad based Bharat Biotech’s Novel Coronavirus or COVID-19 vaccine candidate COVAXIN, showed successful results on animals.
According to the sources, the potential vaccine showed efficacy in animal trials and generated robust immune responses.
This indigenous vaccine is one of the front runners in the race for a coronavirus vaccine in India. The Bharat Biotech with the Indian Council of Medical Research (ICMR) formed a potential candidate vaccine for the Novel Coronavirus.
The vaccine is being tested at 12 institutes across India.
On the 12th of September, the company announced the progress and a positive response on animals. It released a statement regarding the same. The statement read, “Bharat Biotech proudly announces the animal study results of COVAXIN — these results demonstrate the protective efficacy in a live viral challenge model.”
In the trial, a two dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques, divided into four groups.
One group was administered with placebo, while three groups were immunised with three different vaccine candidates at zero and 14 days.
All the macaques were given the antibodies dose and were exposed to the viral Novel Coronavirus for 14 days.
The statement read, “The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of the monkeys.”
The news of progressive result of COVAXIN was seen at a time when India is reporting a minimum of 90,000 cases.
India, on the 12th of September reported a record jump of 1,201 fatalities and 97,000 new cases of the Novel Coronavirus or COVID-19.
With this, till date, India has approximately 4.6 million cases and 77,000 plus deaths.
Stay tuned for further updates.